Merck KGaA Stock Price, News & Analysis (FRA:MRK)

€82.60 -0.04 (-0.05 %)
(As of 02/23/2018 03:05 PM ET)
Previous Close€82.60
Today's Range€81.98 - €82.60
52-Week Range€80.50 - €115.00
Volume139 shs
Average VolumeN/A
Market Capitalization$10.64 billion
P/E Ratio19.34
Dividend Yield1.45%
BetaN/A

About Merck KGaA (FRA:MRK)

Merck KGaA logoMERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders. It also provides over-the-counter products to relieve muscle, joint, and back pain, as well as cold and headaches; probiotic nutritional supplements; vitamin C; and various products with vitamins, minerals, and nutrients that support women's health during pregnancy, nursing, and menopause under the Neurobion, Bion, Femibion, Floratil, Nasivin, Seven Seas, Apaisyl, Cebion, Sangobion, Kytta, Sedalmerck, Vigantoletten, and Doloneurobion brands. In addition, the company offers life science products and services for use in the discovery, development, and manufacture of chemical and biotechnological origin drugs, as well as in research and application laboratories; and specialty chemicals and functional materials for applications consumer electronics, lighting, photovoltaics, printing technology, coatings, plastics, cosmetics, and food industries. MERCK Kommanditgesellschaft auf Aktien has strategic alliances with Pfizer Inc. and Baylor College of Medicine; an agreement with Bristol-Myers Squibb Company for the co-commercialization of Glucophage, an antidiabetic agent in China; a strategic collaboration and license agreement with Intrexon Corporation to co-develop and co-commercialize CAR-T cancer therapies; and collaborations with F-star and Cancer Research Technology. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.

Receive MRK News and Ratings via Email

Sign-up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorHealthcare
SymbolFRA:MRK
CUSIPN/A
Phone+49-6151-720

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio19.344262295082
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares129,240,000

Merck KGaA (FRA:MRK) Frequently Asked Questions

What is Merck KGaA's stock symbol?

Merck KGaA trades on the FRA under the ticker symbol "MRK."

Where is Merck KGaA's stock going? Where will Merck KGaA's stock price be in 2018?

20 brokers have issued 1-year price objectives for Merck KGaA's shares. Their forecasts range from €95.00 to €125.00. On average, they expect Merck KGaA's share price to reach €107.63 in the next year. View Analyst Ratings for Merck KGaA.

Who are some of Merck KGaA's key competitors?

Who are Merck KGaA's key executives?

Merck KGaA's management team includes the folowing people:

  • Wolfgang Buechele, Chairman of the Supervisory Board (Age 58)
  • Stefan Oschmann Ph.D., Chairman of Executive Board and Chief Executive Officer (Age 59)
  • Michael Fletterich, Vice Chairman of the Supervisory Board, Employee Representative (Age 59)
  • Marcus Kuhnert, Member of the Executive Board, Chief Financial Officer
  • Udit Batra, CEO Life Science, Member of the Executive Board (Age 46)
  • Walter Heinrich Galinat, CEO Performance Materials, Member of the Executive Board (Age 61)
  • Belen Garijo, CEO Healthcare, Member of the Executive Board (Age 54)
  • Kai Beckmann, Chief Administrative Officer, Member of the Executive Board (Age 51)
  • Constantin Fest, Head of Investor Relations
  • Constantin Birnstiel, Head of Group Communications

What is Merck KGaA's stock price today?

One share of Merck KGaA stock can currently be purchased for approximately €82.60.

How big of a company is Merck KGaA?

Merck KGaA has a market capitalization of $10.64 billion.

How can I contact Merck KGaA?

Merck KGaA's mailing address is Frankfurter Strasse 250, DARMSTADT, 64293, Germany. The healthcare company can be reached via phone at +49-6151-720.


MarketBeat Community Rating for Merck KGaA (MRK)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  488 (Vote Outperform)
Underperform Votes:  655 (Vote Underperform)
Total Votes:  1,143
MarketBeat's community ratings are surveys of what our community members think about Merck KGaA and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Merck KGaA (FRA:MRK) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyHoldBuyHold
Consensus Rating Score: 2.502.452.502.29
Ratings Breakdown: 0 Sell Rating(s)
10 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
11 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
10 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
15 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: €107.63€107.63€108.95€109.20

Merck KGaA (FRA:MRK) Consensus Price Target History

Price Target History for Merck KGaA (FRA:MRK)

Merck KGaA (FRA:MRK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
2/19/2018JPMorgan Chase & Co.Set Price TargetNeutral€95.00View Rating Details
2/16/2018Warburg ResearchSet Price TargetBuy€115.00View Rating Details
2/12/2018DZ BankReiterated RatingHold -> BuyView Rating Details
1/17/2018Kepler Capital MarketsSet Price TargetBuy€115.00View Rating Details
1/17/2018Sanford C. BernsteinSet Price TargetBuy€115.00View Rating Details
1/2/2018Nord/LBReiterated RatingNeutralView Rating Details
12/6/2017Bank of AmericaSet Price TargetNeutral€95.00View Rating Details
12/1/2017Morgan StanleySet Price TargetNeutral€98.00View Rating Details
11/29/2017Goldman Sachs GroupSet Price TargetNeutral€100.00View Rating Details
11/23/2017Berenberg BankSet Price TargetBuy€116.00View Rating Details
11/10/2017Societe GeneraleSet Price TargetNeutral€101.00View Rating Details
11/10/2017Oddo BhfSet Price TargetBuy€125.00View Rating Details
11/10/2017Deutsche BankSet Price TargetNeutral€99.00View Rating Details
11/9/2017S&P GlobalSet Price TargetBuy€110.00View Rating Details
11/9/2017Independent ResearchSet Price TargetNeutral€103.00View Rating Details
11/9/2017CommerzbankSet Price TargetNeutral€103.00View Rating Details
11/3/2017equinetSet Price TargetBuy€112.00View Rating Details
10/2/2017CitigroupSet Price TargetBuy€123.00View Rating Details
9/6/2017BNP ParibasSet Price TargetBuy€116.00View Rating Details
7/26/2017Credit Suisse GroupSet Price TargetNeutral€106.00View Rating Details
11/15/2016Bankhaus LampeSet Price TargetBuy€112.00View Rating Details
11/15/2016S&P GlobalSet Price TargetNeutral€103.00View Rating Details
8/5/2016Baader BankSet Price TargetNeutral€97.00View Rating Details
5/10/2016BarclaysSet Price TargetNeutral€87.00View Rating Details
(Data available from 2/23/2016 forward)

Earnings

Earnings History for Merck KGaA (FRA:MRK)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Merck KGaA (FRA:MRK) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Merck KGaA (FRA:MRK)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Merck KGaA (FRA MRK)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Merck KGaA (FRA MRK) News Headlines

Source:
DateHeadline
Merck KGaA (MRK) Given a €95.00 Price Target by JPMorgan Chase & Co. AnalystsMerck KGaA (MRK) Given a €95.00 Price Target by JPMorgan Chase & Co. Analysts
www.americanbankingnews.com - February 19 at 12:18 PM
Merck KGaA (MRK) PT Set at €120.00 by UBS GroupMerck KGaA (MRK) PT Set at €120.00 by UBS Group
www.americanbankingnews.com - February 17 at 1:55 PM
Warburg Research Analysts Give Merck KGaA (MRK) a €115.00 Price TargetWarburg Research Analysts Give Merck KGaA (MRK) a €115.00 Price Target
www.americanbankingnews.com - February 17 at 12:42 AM
Your Daily Pharma Scoop: Achaogen Update, Catabasis Positive Results, Bristol-Myers Squibb/Nektar CollaborationYour Daily Pharma Scoop: Achaogen Update, Catabasis' Positive Results, Bristol-Myers Squibb/Nektar Collaboration
seekingalpha.com - February 15 at 4:08 PM
Merck KGaA (MRK) Given Consensus Rating of "Buy" by AnalystsMerck KGaA (MRK) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - February 13 at 11:20 AM
Merck KGaA (MRK) Receives Buy Rating from DZ BankMerck KGaA (MRK) Receives Buy Rating from DZ Bank
www.americanbankingnews.com - February 12 at 1:32 PM
Merck KGaA (MRK) Given a €95.00 Price Target at JPMorgan Chase & Co.Merck KGaA (MRK) Given a €95.00 Price Target at JPMorgan Chase & Co.
www.americanbankingnews.com - February 12 at 6:12 AM
Merck KGaA (MRK) Given Consensus Recommendation of "Hold" by BrokeragesMerck KGaA (MRK) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - January 19 at 8:02 AM
Kepler Capital Markets Reiterates €115.00 Price Target for Merck KGaA (MRK)Kepler Capital Markets Reiterates €115.00 Price Target for Merck KGaA (MRK)
www.americanbankingnews.com - January 17 at 11:22 AM
Merck KGaAs (MRK) "Neutral" Rating Reaffirmed at JPMorgan Chase & Co.Merck KGaA's (MRK) "Neutral" Rating Reaffirmed at JPMorgan Chase & Co.
www.americanbankingnews.com - January 17 at 8:32 AM
Merck KGaA (MRK) Given "Buy" Rating at UBS GroupMerck KGaA (MRK) Given "Buy" Rating at UBS Group
www.americanbankingnews.com - January 15 at 11:02 AM
Nestle frontrunner for Merck KGaAs consumer health business - BloombergNestle frontrunner for Merck KGaA's consumer health business - Bloomberg
finance.yahoo.com - January 10 at 9:33 AM
Morgan Stanley Analysts Give Merck KGaA (MRK) a €98.00 Price TargetMorgan Stanley Analysts Give Merck KGaA (MRK) a €98.00 Price Target
www.americanbankingnews.com - December 30 at 5:14 PM
Merck KGaA (MRK) PT Set at €95.00 by JPMorgan Chase & Co.Merck KGaA (MRK) PT Set at €95.00 by JPMorgan Chase & Co.
www.americanbankingnews.com - December 29 at 2:50 PM
Nord/LB Reiterates Neutral Rating for Merck KGaA (MRK)Nord/LB Reiterates Neutral Rating for Merck KGaA (MRK)
www.americanbankingnews.com - December 27 at 8:48 AM
Merck KGaA (MRK) Given a €100.00 Price Target by JPMorgan Chase & Co. AnalystsMerck KGaA (MRK) Given a €100.00 Price Target by JPMorgan Chase & Co. Analysts
www.americanbankingnews.com - December 25 at 10:06 AM
Merck KGaA (MRK) Given Average Recommendation of "Hold" by BrokeragesMerck KGaA (MRK) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - December 25 at 8:06 AM
Pharma Stock Roundup: Aeries Rhopressa Approved, Label Expansion for BMY, Pfizer DrugsPharma Stock Roundup: Aerie's Rhopressa Approved, Label Expansion for BMY, Pfizer Drugs
finance.yahoo.com - December 23 at 2:31 AM
Merck KGaA (MRK) Given a €95.00 Price Target by Bank of America AnalystsMerck KGaA (MRK) Given a €95.00 Price Target by Bank of America Analysts
www.americanbankingnews.com - December 10 at 9:24 AM
Merck KGaA (MRK) Given a €98.00 Price Target at Nord/LBMerck KGaA (MRK) Given a €98.00 Price Target at Nord/LB
www.americanbankingnews.com - December 8 at 10:34 AM
Merck KGaA (MRK) Given a €120.00 Price Target at UBSMerck KGaA (MRK) Given a €120.00 Price Target at UBS
www.americanbankingnews.com - December 6 at 6:38 AM
Merck KGaA (MRK) Given Consensus Recommendation of "Buy" by AnalystsMerck KGaA (MRK) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - November 30 at 7:50 AM
Merck KGaA (MRK) Given a €115.00 Price Target by Warburg Research AnalystsMerck KGaA (MRK) Given a €115.00 Price Target by Warburg Research Analysts
www.americanbankingnews.com - November 29 at 6:42 PM
Pfizer, Germanys Merck cancer treatment trial misses primary endpoint - MarketWatchPfizer, Germany's Merck cancer treatment trial misses primary endpoint - MarketWatch
www.marketwatch.com - November 29 at 5:40 PM
Goldman Sachs Group Analysts Give Merck KGaA (MRK) a €100.00 Price TargetGoldman Sachs Group Analysts Give Merck KGaA (MRK) a €100.00 Price Target
www.americanbankingnews.com - November 29 at 8:12 AM
Sanford C. Bernstein Analysts Give Merck KGaA (MRK) a €115.00 Price TargetSanford C. Bernstein Analysts Give Merck KGaA (MRK) a €115.00 Price Target
www.americanbankingnews.com - November 29 at 7:30 AM
Merck KGaA (MRK) Earns Neutral Rating from J P Morgan Chase & CoMerck KGaA (MRK) Earns Neutral Rating from J P Morgan Chase & Co
www.americanbankingnews.com - November 28 at 3:36 PM
Merck KGaA, Pfizers Avelumab fails to meet goalMerck KGaA, Pfizer's Avelumab fails to meet goal
www.marketwatch.com - November 28 at 10:14 AM
Merck KGaA, Pfizers avelumab misses goal in gastric cancer trialMerck KGaA, Pfizer's avelumab misses goal in gastric cancer trial
finance.yahoo.com - November 28 at 10:14 AM
Pfizer, Germanys Merck cancer treatment trial misses primary endpointPfizer, Germany's Merck cancer treatment trial misses primary endpoint
finance.yahoo.com - November 28 at 10:14 AM
Merck KGaA, Pfizers immunotherapy fails in gastric cancer trialMerck KGaA, Pfizer's immunotherapy fails in gastric cancer trial
finance.yahoo.com - November 28 at 10:14 AM
Merck KGaA (MRK) Receives "Neutral" Rating from DZ Bank AGMerck KGaA (MRK) Receives "Neutral" Rating from DZ Bank AG
www.americanbankingnews.com - November 25 at 2:52 PM
Merck KGaA (MRK) Given a €100.00 Price Target at Goldman Sachs Group, Inc. (The)Merck KGaA (MRK) Given a €100.00 Price Target at Goldman Sachs Group, Inc. (The)
www.americanbankingnews.com - November 24 at 6:46 PM
Merck KGaA (MRK) Given a €116.00 Price Target by Berenberg Bank AnalystsMerck KGaA (MRK) Given a €116.00 Price Target by Berenberg Bank Analysts
www.americanbankingnews.com - November 23 at 10:14 AM
Merck KGaA (MRK) Given a €115.00 Price Target at Sanford C. BernsteinMerck KGaA (MRK) Given a €115.00 Price Target at Sanford C. Bernstein
www.americanbankingnews.com - November 15 at 7:06 PM
Deutsche Bank AG Analysts Give Merck KGaA (MRK) a €99.00 Price TargetDeutsche Bank AG Analysts Give Merck KGaA (MRK) a €99.00 Price Target
www.americanbankingnews.com - November 12 at 6:32 PM
Societe Generale Reiterates "€101.00" Price Target for Merck KGaA (MRK)Societe Generale Reiterates "€101.00" Price Target for Merck KGaA (MRK)
www.americanbankingnews.com - November 10 at 12:16 PM
Merck KGaA (MRK) Given a €125.00 Price Target at Oddo BhfMerck KGaA (MRK) Given a €125.00 Price Target at Oddo Bhf
www.americanbankingnews.com - November 10 at 6:20 AM
Merck KGaA (MRK) Given a €110.00 Price Target at S&P GlobalMerck KGaA (MRK) Given a €110.00 Price Target at S&P Global
www.americanbankingnews.com - November 9 at 12:25 PM
Merck KGaA (MRK) Given a €98.00 Price Target by Nord/LB AnalystsMerck KGaA (MRK) Given a €98.00 Price Target by Nord/LB Analysts
www.americanbankingnews.com - November 9 at 12:25 PM
UBS AG Analysts Give Merck KGaA (MRK) a €120.00 Price TargetUBS AG Analysts Give Merck KGaA (MRK) a €120.00 Price Target
www.americanbankingnews.com - November 9 at 10:54 AM
Merck KGaA (MRK) PT Set at €115.00 by Kepler Capital MarketsMerck KGaA (MRK) PT Set at €115.00 by Kepler Capital Markets
www.americanbankingnews.com - November 6 at 6:08 AM
Merck KGaA (MRK) Given a €112.00 Price Target by equinet AG AnalystsMerck KGaA (MRK) Given a €112.00 Price Target by equinet AG Analysts
www.americanbankingnews.com - November 5 at 12:50 PM
Merck KGaA (MRK) Given Average Rating of "Hold" by AnalystsMerck KGaA (MRK) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - November 5 at 7:38 AM
Oddo Bhf Analysts Give Merck KGaA (MRK) a €125.00 Price TargetOddo Bhf Analysts Give Merck KGaA (MRK) a €125.00 Price Target
www.americanbankingnews.com - October 27 at 10:34 AM
Pfizer Pops in Pre-Market After Group Considers Consumer Healthcare SalePfizer Pops in Pre-Market After Group Considers Consumer Healthcare Sale
finance.yahoo.com - October 11 at 12:30 AM
Merck KGaA (MRK) Given a €100.00 Price Target at J P Morgan Chase & CoMerck KGaA (MRK) Given a €100.00 Price Target at J P Morgan Chase & Co
www.americanbankingnews.com - October 6 at 11:40 AM
Independent Research GmbH Reiterates €105.00 Price Target for Merck KGaA (MRK)Independent Research GmbH Reiterates €105.00 Price Target for Merck KGaA (MRK)
www.americanbankingnews.com - October 5 at 6:58 PM
Commerzbank Ag Reiterates €109.00 Price Target for Merck KGaA (MRK)Commerzbank Ag Reiterates €109.00 Price Target for Merck KGaA (MRK)
www.americanbankingnews.com - September 29 at 6:38 PM
Merck KGaA (MRK) Given a €123.00 Price Target at Citigroup Inc.Merck KGaA (MRK) Given a €123.00 Price Target at Citigroup Inc.
www.americanbankingnews.com - September 25 at 9:38 AM

SEC Filings

Merck KGaA (FRA:MRK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Merck KGaA (FRA MRK) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.